SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001720725-20-000037
Filing Date
2020-08-05
Accepted
2020-08-05 07:02:04
Documents
16
Period of Report
2020-08-05
Items
Item 2.02: Results of Operations and Financial Condition

Document Format Files

Seq Description Document Type Size
1 8-K oyst-20200805.htm   iXBRL 8-K 46356
2 EX-99.1 oystearningspressrelea.htm EX-99.1 85594
8 oysterpointlogorgb11.jpg GRAPHIC 1157484
  Complete submission text file 0001720725-20-000037.txt   1721517

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT oyst-20200805.xsd EX-101.SCH 2426
4 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT oyst-20200805_cal.xml EX-101.CAL 712
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT oyst-20200805_def.xml EX-101.DEF 1645
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT oyst-20200805_lab.xml EX-101.LAB 24975
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT oyst-20200805_pre.xml EX-101.PRE 13189
9 EXTRACTED XBRL INSTANCE DOCUMENT oyst-20200805_htm.xml XML 11357
Mailing Address 202 CARNEGIE CENTER SUITE 109 PRINCETON NJ 08540
Business Address 202 CARNEGIE CENTER SUITE 109 PRINCETON NJ 08540 (609) 382-9032
Oyster Point Pharma, Inc. (Filer) CIK: 0001720725 (see all company filings)

IRS No.: 811030955 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39112 | Film No.: 201075581
SIC: 2836 Biological Products, (No Diagnostic Substances)